Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out if the addition of nivolumab can improve 2 year
progression free survival (PFS) as compared to standard of care of fractionated radiation
therapy (RT) and carboplatin/paclitaxel in subjects with high risk HPV-related squamous cell
carcinoma of the oropharynx (tonsil, base of tongue, oropharyngeal wall, soft palate).
Fractionated means the radiation will be administered in fragments or parts across multiple
days.